Proficio Capital Partners LLC Makes New $394,000 Investment in Organon & Co. (NYSE:OGN)

Proficio Capital Partners LLC acquired a new position in Organon & Co. (NYSE:OGN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 26,393 shares of the company's stock, valued at approximately $394,000.

Several other large investors also recently added to or reduced their stakes in OGN. Commerce Bank boosted its position in shares of Organon & Co. by 5.5% during the 3rd quarter. Commerce Bank now owns 12,168 shares of the company's stock valued at $233,000 after acquiring an additional 637 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Organon & Co. by 32.4% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock valued at $41,000 after purchasing an additional 672 shares during the period. CIBC Asset Management Inc boosted its stake in shares of Organon & Co. by 4.9% during the fourth quarter. CIBC Asset Management Inc now owns 25,523 shares of the company's stock valued at $381,000 after purchasing an additional 1,184 shares during the period. Deseret Mutual Benefit Administrators lifted its stake in Organon & Co. by 24.3% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 6,256 shares of the company's stock worth $93,000 after acquiring an additional 1,222 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its stake in Organon & Co. by 12.9% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 10,910 shares of the company's stock worth $163,000 after acquiring an additional 1,248 shares during the period. Hedge funds and other institutional investors own 77.43% of the company's stock.

Remove Ads

Organon & Co. Stock Performance

Shares of OGN stock traded up $0.38 during trading hours on Friday, reaching $15.34. 3,034,092 shares of the company traded hands, compared to its average volume of 3,060,926. Organon & Co. has a 12-month low of $13.87 and a 12-month high of $23.10. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The company has a market cap of $3.96 billion, a P/E ratio of 4.61, a P/E/G ratio of 0.90 and a beta of 0.76. The firm has a 50-day moving average price of $15.46 and a 200 day moving average price of $16.78.

Organon & Co. (NYSE:OGN - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. As a group, sell-side analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 7.30%. The ex-dividend date was Monday, February 24th. Organon & Co.'s dividend payout ratio is currently 33.63%.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. TD Cowen raised Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Morgan Stanley reduced their price target on Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a report on Friday, February 14th. Finally, Barclays dropped their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.